Arsenite Exposure Displaces Zinc from ZRANB2 Leading to Altered Splicing
Exposure to arsenic, a class I carcinogen, affects 200 million people globally. Skin is the major target organ, but the molecular etiology of arsenic-induced skin carcinogenesis remains unclear. Arsenite (As )-induced disruption of alternative splicing could be involved, but the mechanism is unknown...
Saved in:
Published in | Chemical research in toxicology Vol. 33; no. 6; pp. 1403 - 1417 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
15.06.2020
|
Online Access | Get full text |
Cover
Loading…
Abstract | Exposure to arsenic, a class I carcinogen, affects 200 million people globally. Skin is the major target organ, but the molecular etiology of arsenic-induced skin carcinogenesis remains unclear. Arsenite (As
)-induced disruption of alternative splicing could be involved, but the mechanism is unknown. Zinc finger proteins play key roles in alternative splicing. As
can displace zinc (Zn
) from C3H1 and C4 zinc finger motifs (zfm's), affecting protein function. ZRANB2, an alternative splicing regulator with two C4 zfm's integral to its structure and splicing function, was chosen as a candidate for this study. We hypothesized that As
could displace Zn
from ZRANB2, altering its structure, expression, and splicing function. As
/Zn
binding and mutual displacement experiments were performed with synthetic apo-peptides corresponding to each ZRANB2 zfm, employing a combination of intrinsic fluorescence, ultraviolet spectrophotometry, zinc colorimetric assay, and liquid chromatography-tandem mass spectrometry. ZRANB2 expression in HaCaT cells acutely exposed to As
(0 or 5 μM, 0-72 h; or 0-5 μM, 6 h) was examined by RT-qPCR and immunoblotting. ZRANB2-dependent splicing of TRA2B mRNA, a known ZRANB2 target, was monitored by reverse transcription-polymerase chain reaction. As
bound to, as well as displaced Zn
from, each zfm. Also, Zn
displaced As
from As
-bound zfm's acutely, albeit transiently. As
exposure induced ZRANB2 protein expression between 3 and 24 h and at all exposures tested but not ZRANB2 mRNA expression. ZRANB2-directed TRA2B splicing was impaired between 3 and 24 h post-exposure. Furthermore, ZRANB2 splicing function was also compromised at all As
exposures, starting at 100 nm. We conclude that As
exposure displaces Zn
from ZRANB2 zfm's, changing its structure and compromising splicing of its targets, and increases ZRANB2 protein expression as a homeostatic response both at environmental/toxicological exposures and therapeutically relevant doses. |
---|---|
AbstractList | Exposure to arsenic, a class I carcinogen, affects 200 million people globally. Skin is the major target organ, but the molecular etiology of arsenic-induced skin carcinogenesis remains unclear. Arsenite (As
)-induced disruption of alternative splicing could be involved, but the mechanism is unknown. Zinc finger proteins play key roles in alternative splicing. As
can displace zinc (Zn
) from C3H1 and C4 zinc finger motifs (zfm's), affecting protein function. ZRANB2, an alternative splicing regulator with two C4 zfm's integral to its structure and splicing function, was chosen as a candidate for this study. We hypothesized that As
could displace Zn
from ZRANB2, altering its structure, expression, and splicing function. As
/Zn
binding and mutual displacement experiments were performed with synthetic apo-peptides corresponding to each ZRANB2 zfm, employing a combination of intrinsic fluorescence, ultraviolet spectrophotometry, zinc colorimetric assay, and liquid chromatography-tandem mass spectrometry. ZRANB2 expression in HaCaT cells acutely exposed to As
(0 or 5 μM, 0-72 h; or 0-5 μM, 6 h) was examined by RT-qPCR and immunoblotting. ZRANB2-dependent splicing of TRA2B mRNA, a known ZRANB2 target, was monitored by reverse transcription-polymerase chain reaction. As
bound to, as well as displaced Zn
from, each zfm. Also, Zn
displaced As
from As
-bound zfm's acutely, albeit transiently. As
exposure induced ZRANB2 protein expression between 3 and 24 h and at all exposures tested but not ZRANB2 mRNA expression. ZRANB2-directed TRA2B splicing was impaired between 3 and 24 h post-exposure. Furthermore, ZRANB2 splicing function was also compromised at all As
exposures, starting at 100 nm. We conclude that As
exposure displaces Zn
from ZRANB2 zfm's, changing its structure and compromising splicing of its targets, and increases ZRANB2 protein expression as a homeostatic response both at environmental/toxicological exposures and therapeutically relevant doses. Exposure to arsenic, a class I carcinogen, affects 200 million people globally. Skin is the major target organ but the molecular etiology of arsenic-induced skin carcinogenesis remains unclear. As 3+ -induced disruption of alternative splicing could be involved, but the mechanism is unknown. Zinc finger proteins play key roles in alternative splicing. Arsenite (As 3+ ) can displace zinc (Zn 2+ ) from C3H1 and C4 zinc finger motifs (zfms), affecting protein function. ZRANB2, an alternative splicing regulator with two C4 zfms integral to its structure and splicing function was chosen as a candidate for this study. We hypothesized that As 3+ could displace Zn 2+ from ZRANB2 altering its structure, expression and splicing function. As 3+ /Zn 2+ binding and mutual displacement experiments were performed with synthetic apo-peptides corresponding to each ZRANB2 zfm, employing a combination of intrinsic fluorescence, UV spectrophotometry, zinc colorimetric assay and liquid chromatography-tandem mass spectrometry. ZRANB2 expression in HaCaT cells acutely exposed to As 3+ (0 or 5 μM; 0-72 h, or 0-5 μM; 6 h) was examined by RT-qPCR and immunoblotting. ZRANB2-dependent splicing of TRA2B mRNA, a known ZRANB2 target, was monitored by RT-PCR. As 3+ bound to, as well as displaced Zn 2+ from, each zfm. Also, Zn 2+ displaced As 3+ from As 3+ -bound zfms acutely, albeit transiently. As 3+ exposure induced ZRANB2 protein expression between 3-24 h and at all exposures tested, but not ZRANB2 mRNA expression. ZRANB2-directed TRA2B splicing was impaired between 3-24 h post-exposure. Furthermore, ZRANB2 splicing function was also compromised at all As 3+ exposures, starting at 100 nm. We conclude that As 3+ exposure displaces Zn 2+ from ZRANB2 zfms, changing its structure and compromising splicing of its targets, and increases ZRANB2 protein expression as a homeostatic response both at environmental/toxicological exposures and therapeutically relevant doses. |
Author | States, J Christopher Pan, Jianmin Wilkey, Daniel W Watson, Walter H Ferragut Cardoso, Ana P Banerjee, Mayukh Lykoudi, Angeliki Rai, Shesh N Garbett, Nichola C Merchant, Michael L |
AuthorAffiliation | Ɨ James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA Division of Nephrology & Hypertension, Department of Medicine, University of Louisville, Louisville, KY, USA Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Louisville, Louisville, KY, USA Biostatistics and Bioinformatics Facility, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY, USA Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY, USA |
AuthorAffiliation_xml | – name: Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA – name: Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY, USA – name: Ɨ James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA – name: Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY, USA – name: Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Louisville, Louisville, KY, USA – name: Biostatistics and Bioinformatics Facility, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA – name: Division of Nephrology & Hypertension, Department of Medicine, University of Louisville, Louisville, KY, USA |
Author_xml | – sequence: 1 givenname: Mayukh surname: Banerjee fullname: Banerjee, Mayukh organization: Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky 40202, United States – sequence: 2 givenname: Ana P surname: Ferragut Cardoso fullname: Ferragut Cardoso, Ana P organization: Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky 40202, United States – sequence: 3 givenname: Angeliki surname: Lykoudi fullname: Lykoudi, Angeliki organization: Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky 40202, United States – sequence: 4 givenname: Daniel W surname: Wilkey fullname: Wilkey, Daniel W organization: Division of Nephrology & Hypertension, Department of Medicine, University of Louisville, Louisville, Kentucky 40202, United States – sequence: 5 givenname: Jianmin surname: Pan fullname: Pan, Jianmin organization: Biostatistics and Bioinformatics Facility, James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky 40202, United States – sequence: 6 givenname: Walter H surname: Watson fullname: Watson, Walter H organization: Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Louisville, Louisville, Kentucky 40202, United States – sequence: 7 givenname: Nichola C surname: Garbett fullname: Garbett, Nichola C organization: James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky 40202, United States – sequence: 8 givenname: Shesh N surname: Rai fullname: Rai, Shesh N organization: Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, Kentucky 40202, United States – sequence: 9 givenname: Michael L surname: Merchant fullname: Merchant, Michael L organization: Division of Nephrology & Hypertension, Department of Medicine, University of Louisville, Louisville, Kentucky 40202, United States – sequence: 10 givenname: J Christopher orcidid: 0000-0003-4717-4422 surname: States fullname: States, J Christopher organization: Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky 40202, United States |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32274925$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkO1KwzAYhYNM3IfewsgNdOajSZo_Qp3TCUPBD5D9CWmbbpGuKUkn8-6tbE799cJ7eM6BZwh6tasNAGOMJhgRfKnzMMnXZuNNaN1uIjOEGGYnYIAZQRFDGPXAACWSRoQkb30wDOEdIdyx4gz0KSEiloQNwDz1wdS2NXC2a1zYegNvbGgqnZsAl7bOYendBi6f0odrAhdGF7ZewdbBtGqNNwV8biqbd79zcFrqKpiLwx2B19vZy3QeLR7v7qfpIspjHLcRxiLDhjNGCDaUMpqRJOEio6JMeCIl5SUXkmaiwBktaMwpSYQWvJC6y5mkI3C172222cYUualbryvVeLvR_lM5bdX_pLZrtXIfSsSIdbtdAd8X5N6F4E15ZDFS325V51b9ulUHtx04_rt8xH5k0i8PFXss |
CitedBy_id | crossref_primary_10_1016_j_taap_2021_115738 crossref_primary_10_1289_EHP9676 crossref_primary_10_1016_j_ecoenv_2023_114823 crossref_primary_10_1007_s00204_021_03084_2 crossref_primary_10_1089_aivt_2020_0026 crossref_primary_10_1016_j_semcancer_2021_09_012 crossref_primary_10_1016_j_taap_2022_116255 crossref_primary_10_1007_s00204_022_03232_2 crossref_primary_10_2174_2210315511666210512025010 crossref_primary_10_1016_j_taap_2022_116042 crossref_primary_10_3390_genes15020257 crossref_primary_10_1016_j_taap_2022_116193 crossref_primary_10_3389_fgene_2024_1389095 crossref_primary_10_1016_j_etap_2022_103921 crossref_primary_10_1016_j_taap_2024_116865 crossref_primary_10_1016_j_semcancer_2021_03_019 crossref_primary_10_1007_s40726_023_00278_3 crossref_primary_10_1016_j_jpha_2024_02_011 |
Cites_doi | 10.1186/s12864-015-1295-9 10.1021/acschembio.6b01135 10.1016/j.taap.2004.12.010 10.1186/s12929-016-0269-9 10.1517/14740338.4.4.769 10.1093/carcin/21.11.2097 10.3123/jemsge.33.128 10.1016/j.toxlet.2005.10.018 10.1007/s00424-018-2136-x 10.1016/j.taap.2013.11.010 10.1158/2159-8290.CD-13-0253 10.1016/j.celrep.2014.12.046 10.1073/pnas.0802466106 10.1016/j.taap.2005.01.048 10.1289/ehp.1205875 10.1074/jbc.M115.663906 10.1039/C8MT00262B 10.2741/s465 10.1182/blood.V89.9.3354 10.1002/cpps.15 10.1016/S0891-5849(00)00209-4 10.1016/j.mrrev.2008.06.003 10.1080/15384047.2016.1139234 10.1021/ja507863d 10.1038/mp.2015.137 10.1007/s11033-013-2637-9 10.1016/j.jes.2016.10.001 10.1021/tx500022j 10.1289/ehp.1103441 10.1038/onc.2013.570 10.1007/s11373-006-9092-8 10.1016/j.jinorgbio.2016.08.003 10.1371/journal.pcbi.1006290 10.1016/j.gene.2012.07.083 10.1038/s41586-019-1651-z 10.1021/acs.chemrestox.8b00062 10.1016/j.canlet.2014.08.016 10.1155/2019/1038932 10.1038/onc.2013.533 10.1093/toxsci/kfy128 10.1038/nmeth.2089 10.1146/annurev-biochem-010909-095056 10.1016/j.jinorgbio.2007.10.021 10.1016/j.sbi.2005.01.006 10.1002/wrna.1476 10.1021/cr300015c 10.1038/ncomms5760 10.1074/mcp.M112.017707 10.1093/toxsci/kfx292 10.1074/jbc.M301896200 10.1021/cr0404390 10.1016/j.semcdb.2017.09.018 10.1016/j.mrfmmm.2003.07.009 10.1021/ic048694q 10.1016/j.hoc.2018.08.001 10.1002/jbt.20112 10.1074/jbc.M805566200 10.1016/j.taap.2008.03.020 10.1155/2013/843781 10.1111/bjh.13890 10.1021/acs.chemrestox.7b00146 10.1016/j.sbi.2005.04.004 10.1136/bcr-2017-222645 10.1038/nri.2016.129 10.1074/jbc.M111.232926 10.1021/ic025969y 10.1016/j.biocel.2007.08.007 10.1016/j.jasms.2009.08.007 10.1038/cddiscovery.2017.71 10.1083/jcb.200010059 10.1016/j.taap.2017.05.031 |
ContentType | Journal Article |
DBID | NPM AAYXX CITATION 5PM |
DOI | 10.1021/acs.chemrestox.9b00515 |
DatabaseName | PubMed CrossRef PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed CrossRef |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1520-5010 |
EndPage | 1417 |
ExternalDocumentID | 10_1021_acs_chemrestox_9b00515 32274925 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIGMS NIH HHS grantid: P20 GM103436 – fundername: NIEHS NIH HHS grantid: R01 ES027778 – fundername: NIGMS NIH HHS grantid: P20 GM113226 – fundername: NIGMS NIH HHS grantid: P30 GM106396 |
GroupedDBID | --- -~X 29B 4.4 55A 5GY 5RE 5VS 7~N AABXI ABJNI ABMVS ABQRX ABUCX ACGFS ACJ ACS ADHLV AEESW AENEX AFEFF AGXLV AHGAQ ALMA_UNASSIGNED_HOLDINGS AQSVZ BAANH CS3 CUPRZ EBS ED~ F5P GGK GNL IH9 IHE JG~ LG6 NPM P2P ROL TN5 UI2 UPT VF5 VG9 W1F YZZ AAYXX CITATION 5PM |
ID | FETCH-LOGICAL-c414t-117b1e655221e3353b28867b37f8689936f6793b7d1b3d3463287a76d9a868593 |
IEDL.DBID | ACS |
ISSN | 0893-228X |
IngestDate | Tue Sep 17 20:59:05 EDT 2024 Fri Dec 06 02:32:16 EST 2024 Sat Sep 28 08:25:00 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
License | https://doi.org/10.15223/policy-029 https://doi.org/10.15223/policy-037 https://doi.org/10.15223/policy-045 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c414t-117b1e655221e3353b28867b37f8689936f6793b7d1b3d3463287a76d9a868593 |
ORCID | 0000-0003-4717-4422 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405655 |
PMID | 32274925 |
PageCount | 15 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7405655 crossref_primary_10_1021_acs_chemrestox_9b00515 pubmed_primary_32274925 |
PublicationCentury | 2000 |
PublicationDate | 2020-06-15 |
PublicationDateYYYYMMDD | 2020-06-15 |
PublicationDate_xml | – month: 06 year: 2020 text: 2020-06-15 day: 15 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Chemical research in toxicology |
PublicationTitleAlternate | Chem Res Toxicol |
PublicationYear | 2020 |
References | ref9/cit9 ref45/cit45 ref3/cit3 ref27/cit27 ref63/cit63 ref56/cit56 ref16/cit16 ref52/cit52 ref23/cit23 ref8/cit8 ref31/cit31 ref59/cit59 ref85/cit85 ref2/cit2 ref77/cit77 ref34/cit34 ref71/cit71 ref37/cit37 ref20/cit20 ref48/cit48 ref60/cit60 ref74/cit74 ref17/cit17 ref10/cit10 ref35/cit35 ref53/cit53 ref19/cit19 ref21/cit21 ref42/cit42 ref46/cit46 ref49/cit49 ref13/cit13 ref61/cit61 ref75/cit75 ref24/cit24 ref38/cit38 ref50/cit50 ref64/cit64 ref54/cit54 ref6/cit6 ref36/cit36 ref18/cit18 ref65/cit65 ref11/cit11 ref25/cit25 ref29/cit29 ref76/cit76 ref32/cit32 ref39/cit39 ref14/cit14 ref57/cit57 ref5/cit5 ref51/cit51 ref43/cit43 ref28/cit28 ref40/cit40 ref26/cit26 ref55/cit55 ref73/cit73 ref12/cit12 ref15/cit15 ref62/cit62 ref41/cit41 ref58/cit58 ref22/cit22 ref33/cit33 ref4/cit4 ref30/cit30 ref47/cit47 ref1/cit1 ref44/cit44 ref7/cit7 |
References_xml | – ident: ref36/cit36 doi: 10.1186/s12864-015-1295-9 – ident: ref30/cit30 doi: 10.1021/acschembio.6b01135 – ident: ref57/cit57 doi: 10.1016/j.taap.2004.12.010 – ident: ref62/cit62 doi: 10.1186/s12929-016-0269-9 – ident: ref4/cit4 doi: 10.1517/14740338.4.4.769 – ident: ref27/cit27 doi: 10.1093/carcin/21.11.2097 – ident: ref2/cit2 doi: 10.3123/jemsge.33.128 – ident: ref35/cit35 doi: 10.1016/j.toxlet.2005.10.018 – ident: ref14/cit14 doi: 10.1007/s00424-018-2136-x – ident: ref32/cit32 doi: 10.1016/j.taap.2013.11.010 – ident: ref18/cit18 doi: 10.1158/2159-8290.CD-13-0253 – ident: ref77/cit77 doi: 10.1016/j.celrep.2014.12.046 – ident: ref37/cit37 doi: 10.1073/pnas.0802466106 – ident: ref7/cit7 doi: 10.1016/j.taap.2005.01.048 – ident: ref1/cit1 doi: 10.1289/ehp.1205875 – ident: ref59/cit59 doi: 10.1074/jbc.M115.663906 – ident: ref85/cit85 doi: 10.1039/C8MT00262B – ident: ref12/cit12 doi: 10.2741/s465 – ident: ref74/cit74 doi: 10.1182/blood.V89.9.3354 – ident: ref53/cit53 doi: 10.1002/cpps.15 – ident: ref76/cit76 doi: 10.1016/S0891-5849(00)00209-4 – ident: ref9/cit9 doi: 10.1016/j.mrrev.2008.06.003 – ident: ref22/cit22 doi: 10.1080/15384047.2016.1139234 – ident: ref29/cit29 doi: 10.1021/ja507863d – ident: ref41/cit41 doi: 10.1038/mp.2015.137 – ident: ref39/cit39 doi: 10.1007/s11033-013-2637-9 – ident: ref73/cit73 doi: 10.1016/j.jes.2016.10.001 – ident: ref49/cit49 – ident: ref46/cit46 doi: 10.1021/tx500022j – ident: ref55/cit55 doi: 10.1289/ehp.1103441 – ident: ref20/cit20 doi: 10.1038/onc.2013.570 – ident: ref8/cit8 doi: 10.1007/s11373-006-9092-8 – ident: ref28/cit28 doi: 10.1016/j.jinorgbio.2016.08.003 – ident: ref63/cit63 doi: 10.1371/journal.pcbi.1006290 – ident: ref21/cit21 doi: 10.1016/j.gene.2012.07.083 – ident: ref16/cit16 doi: 10.1038/s41586-019-1651-z – ident: ref44/cit44 doi: 10.1021/acs.chemrestox.8b00062 – ident: ref10/cit10 doi: 10.1016/j.canlet.2014.08.016 – ident: ref75/cit75 doi: 10.1155/2019/1038932 – ident: ref19/cit19 doi: 10.1038/onc.2013.533 – ident: ref11/cit11 doi: 10.1093/toxsci/kfy128 – ident: ref51/cit51 doi: 10.1038/nmeth.2089 – ident: ref60/cit60 doi: 10.1146/annurev-biochem-010909-095056 – ident: ref58/cit58 doi: 10.1016/j.jinorgbio.2007.10.021 – ident: ref25/cit25 doi: 10.1016/j.sbi.2005.01.006 – ident: ref15/cit15 doi: 10.1002/wrna.1476 – ident: ref34/cit34 doi: 10.1021/cr300015c – ident: ref43/cit43 doi: 10.1038/ncomms5760 – ident: ref47/cit47 doi: 10.1074/mcp.M112.017707 – ident: ref50/cit50 doi: 10.1093/toxsci/kfx292 – ident: ref26/cit26 doi: 10.1074/jbc.M301896200 – ident: ref48/cit48 doi: 10.1021/cr0404390 – ident: ref17/cit17 doi: 10.1016/j.semcdb.2017.09.018 – ident: ref13/cit13 doi: 10.1016/j.mrfmmm.2003.07.009 – ident: ref45/cit45 doi: 10.1021/ic048694q – ident: ref5/cit5 doi: 10.1016/j.hoc.2018.08.001 – ident: ref56/cit56 doi: 10.1002/jbt.20112 – ident: ref33/cit33 doi: 10.1074/jbc.M805566200 – ident: ref52/cit52 doi: 10.1016/j.taap.2008.03.020 – ident: ref42/cit42 doi: 10.1155/2013/843781 – ident: ref3/cit3 doi: 10.1111/bjh.13890 – ident: ref65/cit65 doi: 10.1021/acs.chemrestox.7b00146 – ident: ref24/cit24 doi: 10.1016/j.sbi.2005.04.004 – ident: ref6/cit6 doi: 10.1136/bcr-2017-222645 – ident: ref23/cit23 doi: 10.1038/nri.2016.129 – ident: ref31/cit31 doi: 10.1074/jbc.M111.232926 – ident: ref71/cit71 doi: 10.1021/ic025969y – ident: ref38/cit38 doi: 10.1016/j.biocel.2007.08.007 – ident: ref54/cit54 doi: 10.1016/j.jasms.2009.08.007 – ident: ref61/cit61 doi: 10.1038/cddiscovery.2017.71 – ident: ref40/cit40 doi: 10.1083/jcb.200010059 – ident: ref64/cit64 doi: 10.1016/j.taap.2017.05.031 |
SSID | ssj0011027 |
Score | 2.464135 |
Snippet | Exposure to arsenic, a class I carcinogen, affects 200 million people globally. Skin is the major target organ, but the molecular etiology of arsenic-induced... Exposure to arsenic, a class I carcinogen, affects 200 million people globally. Skin is the major target organ but the molecular etiology of arsenic-induced... |
SourceID | pubmedcentral crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 1403 |
Title | Arsenite Exposure Displaces Zinc from ZRANB2 Leading to Altered Splicing |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32274925 https://pubmed.ncbi.nlm.nih.gov/PMC7405655 |
Volume | 33 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bS8MwFD4MnwTxMm_zRh5kT3YuSZu0j3VuDNHhFYYvJZcOh9jJ1oH6602aXRwy0NcmKc05ac53cs75AnCqFBNccuqxutCeL7jyJI2wR1SkhPIjXxeB9psOaz_5V92gW4L6kgg-wedCGeG_pG_2qorBR63g8CuqyglnNocvbjzMwgZmgKP2jKhHSNidlgQvfc2CNZqZoMX0yB_2prUBd9OqHZdm8lob57Kmvn6TOP55KpuwPgGfKHarZQtKaVaG6q1jr_48Q4_zYqzRGaqi2zmv9WcZ1twRH3KVS9vQjoej1EJW1Px4H9iTRnTZH7kkL_TczxSytSvo-T7uXBB07bL1UT5AsY3Qpxo92Ni5ebYDT63mY6PtTS5m8JSP_dzDmEucssBgN5xSGlBJwpBxSXkvZMaBo6zHzH8vucaSauozavwywZmOhGkPIroLK9kgS_cBWQazujC7DDVISGgW6p5UVGKDWrjUnFXgfKqg5N3xbyRF3JzgxIgzmYszmYizAntOfbP-Zs_iloOxAnxBsbMOlmJ7sSXrvxRU29zgWTPPg39_xSGsEuuZ21uOgiNYyYfj9NjAl1yeFEv2G01l7kw |
link.rule.ids | 230,314,780,784,885,2765,27924,27925 |
linkProvider | American Chemical Society |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Arsenite+Exposure+Displaces+Zinc+from+ZRANB2+Leading+to+Altered+Splicing&rft.jtitle=Chemical+research+in+toxicology&rft.au=Banerjee%2C+Mayukh&rft.au=Ferragut+Cardoso%2C+Ana+P.&rft.au=Lykoudi%2C+Angeliki&rft.au=Wilkey%2C+Daniel+W.&rft.date=2020-06-15&rft.issn=0893-228X&rft.eissn=1520-5010&rft.volume=33&rft.issue=6&rft.spage=1403&rft.epage=1417&rft_id=info:doi/10.1021%2Facs.chemrestox.9b00515&rft.externalDBID=n%2Fa&rft.externalDocID=10_1021_acs_chemrestox_9b00515 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0893-228X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0893-228X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0893-228X&client=summon |